NasdaqGS:CRNXPharmaceuticals
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Brazil ANVISA Filing For PALSONIFY
Crinetics Pharmaceuticals (CRNX) recently submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints.
See our latest analysis for Crinetics Pharmaceuticals.
The Brazil filing arrives after a strong run in recent days, with a 7 day share price return of 10.01% partly offsetting a weaker year to date share price return of 19.32% and contrasting with a 1...